EnglishRaiffeisen Research recommends Zentiva shares for purchase based on an estimate of 1.654 CZH for 12 months, compared to the previous estimate of 1.540 CZK. the latest analysis also considers Zentiva"s acquisition of Eczacibasi - Turkey for 460 million EUR.
IMS estimates that Turkey is going to become one of the top 10 pharmaceutical markets, having the fastest growth rate in Eastern Europe and being one of the most dynamic markets in the world.
Among the growth drivers are the replacement of obsolete medicines with modern ones, a growing population with a higher life expectancy, the GDP increase, the increasing in the purchase power and health system reform.
Turkey will be Zentiva"s fourth market, after the Czech Republic, Slovakia and Romania. The acquisition in Turkey stands for 5% of the Turkish pharma market volume and 3% of the value. Raiffeisen analysts estimate sales of 18.64 million CZK this year, up by 33.1% from 2006. The projection for 2008 is +27.4%.
Euro
Dolar SUA
Franc elveţian
Liră sterlină
Gram de aur
